Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Enanta Pharma Stock (NASDAQ: ENTA) stock price, news, charts, stock research, profile.
Open12.520 | Close- |
Vol / Avg.127.019K / 387.666K | Mkt Cap250.349M |
Day Range11.960 - 12.610 | 52 Wk Range11.560 - 62.060 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.330 | -1.860 | 0.4700 | ||||
REV | 18.060M | 18.892M | 832.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-19 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-09 | Oppenheimer | Jay Olson | Maintains | PerformPerform | Lowers | 30.00 | 25.00 |
2023-08-08 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 48.00 |
2023-08-08 | RBC Capital | Brian Abrahams | Reiterates | Sector PerformSector Perform | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ENTA | Enanta Pharma | -5.78% | 250.3M |
MGNX | Macrogenics | 1.87% | 286.5M |
ZURA | Zura Bio | 2.58% | 268.8M |
SPRY | ARS Pharmaceuticals | 22.95% | 343.1M |
HUMA | Humacyte | 2.04% | 310.3M |
You can purchase shares of Enanta Pharma (NASDAQ: ENTA) through any online brokerage.
Other companies in Enanta Pharma’s space includes: Macrogenics (NASDAQ:MGNX), Zura Bio (NASDAQ:ZURA), ARS Pharmaceuticals (NASDAQ:SPRY), Humacyte (NASDAQ:HUMA) and Inozyme Pharma (NASDAQ:INZY).
The latest price target for Enanta Pharma (NASDAQ: ENTA) was reported by HC Wainwright & Co. on Tuesday, September 19, 2023. The analyst firm set a price target for 48.00 expecting ENTA to rise to within 12 months (a possible 303.70% upside). 17 analyst firms have reported ratings in the last year.
The stock price for Enanta Pharma (NASDAQ: ENTA) is $11.89 last updated Today at September 21, 2023 at 6:27 PM UTC.
There is no dividend information for Enanta Pharma.
Enanta Pharma’s Q4 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for Enanta Pharma.
Enanta Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.